CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Predictors of health care provideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1896 Predictors adverse evolution Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Clinical Characterization of CoVid19 Infection: Prognostic Stratification and Complications

1. Objectives: 1.-To create risk stratification scales of poor evolution in patients infected by SARS-CoV-2. 2.-Evaluate the accessibility and equity that these patients have had in the different care processes, diagnostic and therapeutic procedures, with special interest in patients who came from residences, by age, gender or geographic origin.3.-Evaluate the effectiveness of different therapeutic schemes that have been used in this pandemic. 4.-Evaluate the effectiveness of different diagnostic tests used to predict the poor evolution of these patients 5.- Evaluate the real costs associated with the treatment of hospitalized patients with COVID-19 ; 2. Methods: Information will be recorded from electronic medical record: epidemiological data, onset of symptoms, comorbidities and their treatments, symptoms, analytical data, vital signs, tests performed, treatments during admission and evolution up to 3 months after discharge. Statistical analysis: The investigators will use classic survival models, logistic regression, generalized linear models and also analysis using artificial intelligence techniques . Health care costs are assessed. Applications for decision making will be derived as a product.

NCT04463706 Covid19 Other: Predictors adverse evolution Other: Predictors of health care provide

Primary Outcomes

Description: Clinical deterioration: Resting dyspnoea (Breathing rate > 30 breaths/minute) or 93% oxygen saturation at rest and partial pressure of arterial oxygen ; (PaO2) /Inspired fraction of O2 <300 mm Hg Development of ARDS, sepsis, SIRS, shock entry in ICU(date and days of stay) Decease (date)

Measure: Clinical deterioration

Time: Admission

Secondary Outcomes

Description: Relief of symptoms (days), days until absence of disease (negative test), .

Measure: Relief of symptoms

Time: Admission

Description: Mortality

Measure: Mortality

Time: 6 months

Description: readmissions, clinical complications

Measure: Complications at follow up

Time: 6 months

Description: Economic cost

Measure: Cost

Time: Admission


No related HPO nodes (Using clinical trials)